RESUMEN
Although high upfront costs for the high value of gene therapy have resulted in concerns about sufficient reimbursement to allow patient access to these therapies, the significant benefits of gene therapies will not be realized unless patients have access to them. Stakeholders are discussing these issues, and the payment models being developed for the newly approved gene therapies provide an early indication of the flexibility that will be needed from treatment manufacturers, payers, and policy makers to optimize patient access. Maximizing patient access to effective gene therapies is one integral part of the overall mission of the American Society of Gene and Cell Therapy, along with maximizing the quality of therapies and minimizing their costs.
Asunto(s)
Terapia Genética , Accesibilidad a los Servicios de Salud , Mejoramiento de la Calidad , Animales , Costo de Enfermedad , Análisis Costo-Beneficio , Terapia Genética/efectos adversos , Terapia Genética/economía , Terapia Genética/métodos , Terapia Genética/tendencias , Costos de la Atención en Salud , Humanos , Evaluación de Resultado en la Atención de Salud , Mecanismo de ReembolsoRESUMEN
A new infrastructure is urgently needed at the global level to facilitate exchange on key issues concerning genome editing. We advocate the establishment of a global observatory to serve as a center for international, interdisciplinary, and cosmopolitan reflection. This article is the first of a two-part series.
Asunto(s)
Discusiones Bioéticas , Edición Génica/ética , Edición Génica/legislación & jurisprudencia , HumanosRESUMEN
A new infrastructure is urgently needed at the global level to facilitate exchange on key issues concerning genome editing. We advocate the establishment of a global observatory to serve as a center for international, interdisciplinary, and cosmopolitan reflection. This article is the second of a two-part series.